Pathological analysis of 42 patients with tamoxifen associated endometrial cancer
10.3760/cma.j.issn.1674-6090.2012.02.011
- VernacularTitle:42例乳腺癌患者服用三苯氧胺并发子宫内膜癌临床病理分析
- Author:
Dongdong SONG
;
Haibo WANG
;
Cunhua ZOU
;
Xueqiang GAO
;
Jianguo ZHANG
;
Jing WANG
- Publication Type:Journal Article
- Keywords:
Tamoxifen;
Breast cancer;
Endometrial cancer;
Clinicopathology
- From:
Journal of Endocrine Surgery
2012;06(2):109-111
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo study the clinicopathological features of endometrial cancer patients diagnosed during or after tamoxifen (TAM)treatment for breast cancer and to evaluate the relevance between the clinicopathological features and the cessation time of TAM treatment. Methods42 TAM-related endometrial cancers patients in the Affiliated Hospital of Medical Collage of Qingdao University were divided into 2 groups according to the cessation time of TAM.Group B were 20 past TAM users who were diagnosed as endometrial cancer 12 or more months since the cessation of TAM.Group A included the rest 22 patients.The clinicopathological features of the 2 groups were analyzed retrospectively.ResultsThe age of patients was ranging from 32 to 85 years when they were diagnosed endometrial cancer.There was no significant difference in terms of the age at which breast cancer was diagnosed, BMI, HRT, single dose of TAM, duration and cumulative dose between the 2 groups.However, the difference of the age at which endometrial cancer was diagnosed, menopausal status, the interval between diagnostic date of the 2 cancers, histological types, pathological stage, myometrial invasion, and cervical invasion had statistical significance between the 2 groups ( P ＜ 0.05 ). Conclusion Compared with group A, group B have a higher pathological stage and more invasive histological features, which may be because group B include more elderly and postmenopausal patients.
